Zilarbi CN 10 Tablet is a combination antihypertensive medication containing Azilsartan medoxomil 40 mg and Cilnidipine 10 mg. Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby preventing vasoconstriction and aldosterone secretion, leading to effective blood pressure reduction. Cilnidipine is a calcium channel blocker of the dihydropyridine class that inhibits L-type and N-type calcium channels, resulting in vasodilation and decreased peripheral vascular resistance. The synergistic action of these two agents provides enhanced antihypertensive efficacy by targeting different pathways involved in blood pressure regulation. Zilarbi CN 10 is indicated for the management of essential hypertension, particularly in patients who require combination therapy to achieve optimal blood pressure control. It may also offer benefits in reducing cardiovascular risk associated with hypertension. The tablet should be taken orally as prescribed by a healthcare professional, with dosage adjustments based on therapeutic response and tolerability. Common adverse effects may include dizziness, headache, and peripheral edema. Use with caution in patients with hepatic or renal impairment. Regular monitoring of blood pressure and renal function is recommended during treatment with Zilarbi CN 10 Tablet.